Outcome of Chemotherapy with Pulmonary Tuberculosis Resistant to Isoniazid and Rifampin

다제내성 폐결핵의 화학치료

  • Park, Seung-Kyu (Clinical Institute, National Masan Tuberculosis Hospital) ;
  • Kwon, Eun-Soo (Clinical Institute, National Masan Tuberculosis Hospital) ;
  • Ha, Hyun-Cheol (Clinical Institute, National Masan Tuberculosis Hospital) ;
  • Hwang, Su-Hee (Clinical Institute, National Masan Tuberculosis Hospital)
  • Published : 1999.01.30

Abstract

Background : The treatment for multi-drug resistant tuberculosis(MDRTB) is encountered to be important clinically, but there are still a few reports about it all over the world. So, we evaluated the outcomes of only chemotherapy for the pulmonary MDRTB retrospectively. Method: We reviewed the clinical courses of 63 patients with pulmonary disease due to M.tuberculosis resistant to rifampin and isoniazid who were under follow-up between March 1996 and June 1996 after hospitalization at our hospital between January 1993 and January 1996. We performed cohort retrospective study for all these patient's records. Their regimens were selected individually and preferably included four medications that they had not been given previously and to which the strain was fully susceptible. Results: The 63 patients(mean age, 43.2 years) had previously received a median 5.1drugs. Fifty two(82.5%) patients responded to chemotherapy(as indicated by negative sputum cultures for at least three consecutive months) ; eleven patients(17.5 %) had no response, as shown by continually positive cultures. In a univariate analysis, an unfavorable response was significantly associated with greater number of resistant drugs before the current courses of therapy(relative risk 21.5 ; 95 percent confidence interval, 1.2-3.0; p<0.05). The mean period of follow-up was seventeen months. There was no relapse suooequently among the patients with responses. There was no death related to tuberculosis. Conclusion: In this report from National Masan Tuberculosis Hospital in Korea, multi-drug resistant pulmonary tuberculosis responded relatively well to carefully selected regimens.

연구배경: 다제내성폐결핵환자의 치료는 임상적으로 심각한 문제를 야기하고 있으나 이에 대한 보고는 거의 없는 상황이다. 이에 저자 등은 다제내성폐결핵환자의 치료처방에 따른 치료성적을 후향적으로 조사하여 보고하는 바이다. 방 법: 1993년 1월부터 1996년 1월까지 국립마산결핵병원에 입원하여 M. tuberculosis에 의한 폐결핵으로 치료를 받은 환자 중 INH와 RMP을 포함하는 항결핵제에 내성이 있는 63명의 임상적 경과를 조사하여 코호트분석(cohort retrospective study)을 시행하였다. 결 과: 환자의 평균 연령은 38.3세였고 이전에 투여받은 약제의 수는 평균 5가지였으며 내성약제의 수는 평균 4가지였다. 화학요법에 의하여 객담배양검사상 연속적으로 3개월이상 음성으로 나타난 치료성공군운 전체 63례 중 52례(82.5%)였고 11례(17.5%)에서는 반응이 없었다. Univariate analysis로 통계처리한 결과가 좋지 않았던 환자는 내성약제의 수와 밀접한 연관을 보였다.(비교위험도 21.5 ; 95% 신뢰구간, 1.2-3.0; p<0.05) 평균추적기간은 17개월이었고 치료에 반응을 보인 환자들중 재발은 없었으며 결핵으로 인한 사망은 없었다. 결 론: 저자의 연구에 의하면 다제내성결핵이라할지라도 잘 선택된 약제의 투여로 비교적 좋은 성적을 기대할 수 있다.

Keywords